<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="EN" article-type="letter"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-title>Diabetologia</journal-title><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19609501</article-id><article-id pub-id-type="pmc">2723677</article-id><article-id pub-id-type="publisher-id">1452</article-id><article-id pub-id-type="doi">10.1007/s00125-009-1452-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Rosenstock</surname><given-names>J.</given-names></name><address><email>juliorosenstock@dallasdiabetes.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fonseca</surname><given-names>V.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McGill</surname><given-names>J. B.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Riddle</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hallé</surname><given-names>J. P.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hramiak</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Johnston</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davis</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label>University of Texas Southwestern Medical School, Dallas, TX USA </aff><aff id="Aff2"><label>2</label>Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane C-685, Dallas, TX 75230 USA </aff><aff id="Aff3"><label>3</label>Tulane University Medical Center, New Orleans, LA USA </aff><aff id="Aff4"><label>4</label>Washington University School of Medicine, St Louis, MO USA </aff><aff id="Aff5"><label>5</label>Oregon Health and Science University, Portland, OR USA </aff><aff id="Aff6"><label>6</label>Université de Montréal, Montréal, QC Canada </aff><aff id="Aff7"><label>7</label>University of Western Ontario, London, ON Canada </aff><aff id="Aff8"><label>8</label>sanofi-aventis, Bridgewater, NJ USA </aff><aff id="Aff9"><label>9</label>University of Wisconsin School of Medicine and Public Health, Madison, WI USA </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>7</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><volume>52</volume><issue>9</issue><fpage>1971</fpage><lpage>1973</lpage><history><date date-type="received"><day>26</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>© The Author(s) 2009</copyright-statement></permissions><kwd-group><title>Keywords</title><kwd>Cancer</kwd><kwd>Insulin analogues</kwd><kwd>Insulin glargine</kwd><kwd>Insulin therapy</kwd><kwd>Malignancy</kwd><kwd>NPH insulin</kwd><kwd>Type 2 diabetes</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer-Verlag 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><p><italic><offsets xml_i="4313" xml_f="4327" txt_i="7" txt_f="21">To the Editor:</offsets></italic><offsets xml_i="4336" xml_f="4593" txt_i="21" txt_f="278"> We have reported a randomised, long-term safety study comparing the effects of using the insulin analogue glargine (A21Gly,B31Arg,B32Arg human insulin) versus human neutral protamine Hagedorn (NPH) insulin for 5 years in the management of type 2 diabetes [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="4625" xml_f="4626" txt_i="278" txt_f="279">1</offsets></xref><offsets xml_i="4633" xml_f="5019" txt_i="279" txt_f="665">]. The study, in which 1017 patients were randomised and treated, was designed to assess ocular complications of diabetes: there was no excess of such effects with insulin glargine compared with NPH insulin treatment and there was a similar slow progression of diabetic retinopathy with both types of insulin. Because of recent concerns about postulated neoplastic effects of insulins [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="5051" xml_f="5052" txt_i="665" txt_f="666">2</offsets></xref><offsets xml_i="5059" xml_f="5060" txt_i="666" txt_f="667">–</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="5092" xml_f="5093" txt_i="667" txt_f="668">5</offsets></xref><offsets xml_i="5100" xml_f="5184" txt_i="668" txt_f="752">], we report here additional information from our study that bears on this question.</offsets></p><p><offsets xml_i="5191" xml_f="5457" txt_i="753" txt_f="1019">In total, the mean cumulative exposure in our study was more than 4 years (1,524 days in the insulin glargine group and 1,522 days in the NPH insulin group), with more than 70% of patients exposed to more than 4 years of treatment (76% and 71%, respectively) (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="5491" xml_f="5492" txt_i="1019" txt_f="1020">1</offsets></xref><offsets xml_i="5499" xml_f="5502" txt_i="1020" txt_f="1023">).
</offsets><table-wrap id="Tab1"><label><offsets xml_i="5531" xml_f="5538" txt_i="1023" txt_f="1030">Table 1</offsets></label><caption><p><offsets xml_i="5558" xml_f="5607" txt_i="1030" txt_f="1079">Summary of extent of exposure (safety population)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="5673" xml_f="5681" txt_i="1080" txt_f="1088">Variable</offsets></th><th><offsets xml_i="5690" xml_f="5708" txt_i="1088" txt_f="1106">Insulin glargine (</offsets><italic><offsets xml_i="5716" xml_f="5718" txt_i="1106" txt_f="1108">n </offsets></italic><offsets xml_i="5727" xml_f="5733" txt_i="1108" txt_f="1114">= 514)</offsets></th><th><offsets xml_i="5742" xml_f="5755" txt_i="1114" txt_f="1127">NPH insulin (</offsets><italic><offsets xml_i="5763" xml_f="5764" txt_i="1127" txt_f="1128">n</offsets></italic><offsets xml_i="5773" xml_f="5780" txt_i="1128" txt_f="1135"> = 503)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="5813" xml_f="5848" txt_i="1135" txt_f="1170">Cumulative exposure (patient-years)</offsets></td><td><offsets xml_i="5857" xml_f="5863" txt_i="1171" txt_f="1177">2144.0</offsets></td><td><offsets xml_i="5872" xml_f="5878" txt_i="1178" txt_f="1184">2095.8</offsets></td></tr><tr><td colspan="3"><offsets xml_i="5908" xml_f="5933" txt_i="1185" txt_f="1210">Extent of exposure (days)</offsets></td></tr><tr><td><offsets xml_i="5951" xml_f="5956" txt_i="1211" txt_f="1216"> Mean</offsets></td><td><offsets xml_i="5965" xml_f="5981" txt_i="1217" txt_f="1233">1523.55 ± 571.77</offsets></td><td><offsets xml_i="5990" xml_f="6006" txt_i="1234" txt_f="1250">1521.82 ± 562.14</offsets></td></tr><tr><td><offsets xml_i="6024" xml_f="6031" txt_i="1251" txt_f="1258"> Median</offsets></td><td><offsets xml_i="6040" xml_f="6047" txt_i="1259" txt_f="1266">1821.50</offsets></td><td><offsets xml_i="6056" xml_f="6063" txt_i="1267" txt_f="1274">1823.00</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="6109" xml_f="6149" txt_i="1275" txt_f="1315">Data are mean±SD unless otherwise stated</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="6191" xml_f="6380" txt_i="1317" txt_f="1506">The baseline demographics and diabetes status were similar between the two treatment groups (insulin glargine vs NPH insulin): diabetes duration (10.7 vs 10.8 years), BMI (34.5 vs 34.1 kg/m</offsets><sup><offsets xml_i="6385" xml_f="6386" txt_i="1506" txt_f="1507">2</offsets></sup><offsets xml_i="6392" xml_f="6484" txt_i="1507" txt_f="1599">), oral hypoglycaemic agent duration (9.0 vs 8.9 years), prior insulin use (67% vs 70%), HbA</offsets><sub><offsets xml_i="6489" xml_f="6491" txt_i="1599" txt_f="1601">1c</offsets></sub><offsets xml_i="6497" xml_f="6562" txt_i="1601" txt_f="1666"> (8.4% vs 8.3%) and fasting plasma glucose (10.5 vs 10.0 mmol/l).</offsets></p><p><offsets xml_i="6569" xml_f="7304" txt_i="1667" txt_f="2402">Although the study was not designed to investigate the frequency of tumour development, the long duration of the trial enables a comparative assessment of the occurrence of benign or malignant tumours with insulin glargine and NPH insulin during more than 4 years of exposure, captured as adverse events in the course of routine safety monitoring. The number of patients with treatment-emergent adverse events (defined as events that first occurred or worsened after randomisation) of neoplasm, summarised by System Organ Class and High-level Group Term levels using the standard Medical Dictionary for Regulatory Activities (MedDRA) coding dictionary (version 10.0; Maintenance and Support Services Organization, Chantilly, VA, USA) [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="7336" xml_f="7337" txt_i="2402" txt_f="2403">6</offsets></xref><offsets xml_i="7344" xml_f="7366" txt_i="2403" txt_f="2425">], are shown in Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="7400" xml_f="7401" txt_i="2425" txt_f="2426">2</offsets></xref><offsets xml_i="7408" xml_f="7591" txt_i="2426" txt_f="2609">. Benign and malignant tumours reported by the investigators, along with those of unspecified pathology, are included. A more detailed listing of MedDRA-coded neoplasms is available [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="7623" xml_f="7624" txt_i="2609" txt_f="2610">7</offsets></xref><offsets xml_i="7631" xml_f="7634" txt_i="2610" txt_f="2613">].
</offsets><table-wrap id="Tab2"><label><offsets xml_i="7663" xml_f="7670" txt_i="2613" txt_f="2620">Table 2</offsets></label><caption><p><offsets xml_i="7690" xml_f="7759" txt_i="2620" txt_f="2689">Patients with neoplasms reported as treatment-emergent adverse events</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="7825" xml_f="7838" txt_i="2690" txt_f="2703">All neoplasms</offsets><sup><bold><offsets xml_i="7849" xml_f="7850" txt_i="2703" txt_f="2704">a</offsets></bold></sup></th><th><offsets xml_i="7872" xml_f="7890" txt_i="2704" txt_f="2722">Insulin glargine (</offsets><italic><offsets xml_i="7898" xml_f="7900" txt_i="2722" txt_f="2724">n </offsets></italic><offsets xml_i="7909" xml_f="7915" txt_i="2724" txt_f="2730">= 514)</offsets></th><th><offsets xml_i="7924" xml_f="7937" txt_i="2730" txt_f="2743">NPH insulin (</offsets><italic><offsets xml_i="7945" xml_f="7947" txt_i="2743" txt_f="2745">n </offsets></italic><offsets xml_i="7956" xml_f="7962" txt_i="2745" txt_f="2751">= 503)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="7995" xml_f="8004" txt_i="2751" txt_f="2760">Any event</offsets></td><td><offsets xml_i="8013" xml_f="8022" txt_i="2761" txt_f="2770">57 (11.1)</offsets></td><td><offsets xml_i="8031" xml_f="8040" txt_i="2771" txt_f="2780">62 (12.3)</offsets></td></tr><tr><td><offsets xml_i="8058" xml_f="8086" txt_i="2781" txt_f="2809"> Breast neoplasms, malignant</offsets></td><td><offsets xml_i="8095" xml_f="8102" txt_i="2810" txt_f="2817">3 (0.6)</offsets></td><td><offsets xml_i="8111" xml_f="8118" txt_i="2818" txt_f="2825">5 (1.0)</offsets></td></tr><tr><td><offsets xml_i="8136" xml_f="8164" txt_i="2826" txt_f="2854"> Cutaneous neoplasms, benign</offsets></td><td><offsets xml_i="8173" xml_f="8181" txt_i="2855" txt_f="2863">13 (2.5)</offsets></td><td><offsets xml_i="8190" xml_f="8198" txt_i="2864" txt_f="2872">12 (2.4)</offsets></td></tr><tr><td><offsets xml_i="8216" xml_f="8247" txt_i="2873" txt_f="2904"> Endocrine neoplasms, malignant</offsets></td><td><offsets xml_i="8256" xml_f="8263" txt_i="2905" txt_f="2912">5 (1.0)</offsets></td><td><offsets xml_i="8272" xml_f="8279" txt_i="2913" txt_f="2920">7 (1.4)</offsets></td></tr><tr><td><offsets xml_i="8297" xml_f="8335" txt_i="2921" txt_f="2959"> Gastrointestinal neoplasms, malignant</offsets></td><td><offsets xml_i="8344" xml_f="8351" txt_i="2960" txt_f="2967">6 (1.2)</offsets></td><td><offsets xml_i="8360" xml_f="8367" txt_i="2968" txt_f="2975">9 (1.8)</offsets></td></tr><tr><td><offsets xml_i="8385" xml_f="8410" txt_i="2976" txt_f="3001"> Haematopoietic neoplasms</offsets></td><td><offsets xml_i="8419" xml_f="8426" txt_i="3002" txt_f="3009">1 (0.2)</offsets></td><td><offsets xml_i="8435" xml_f="8436" txt_i="3010" txt_f="3011">0</offsets></td></tr><tr><td><offsets xml_i="8454" xml_f="8489" txt_i="3012" txt_f="3047"> Hepatobiliary neoplasms, malignant</offsets></td><td><offsets xml_i="8498" xml_f="8499" txt_i="3048" txt_f="3049">0</offsets></td><td><offsets xml_i="8508" xml_f="8515" txt_i="3050" txt_f="3057">1 (0.2)</offsets></td></tr><tr><td><offsets xml_i="8533" xml_f="8565" txt_i="3058" txt_f="3090"> Lymphomas, non-Hodgkin's B cell</offsets></td><td><offsets xml_i="8574" xml_f="8575" txt_i="3091" txt_f="3092">0</offsets></td><td><offsets xml_i="8584" xml_f="8591" txt_i="3093" txt_f="3100">1 (0.2)</offsets></td></tr><tr><td><offsets xml_i="8609" xml_f="8642" txt_i="3101" txt_f="3134"> Metastases, unspecified neoplasm</offsets></td><td><offsets xml_i="8651" xml_f="8652" txt_i="3135" txt_f="3136">0</offsets></td><td><offsets xml_i="8661" xml_f="8668" txt_i="3137" txt_f="3144">1 (0.2)</offsets></td></tr><tr><td><offsets xml_i="8686" xml_f="8742" txt_i="3145" txt_f="3201"> Miscellaneous and site unspecified neoplasms, malignant</offsets></td><td><offsets xml_i="8751" xml_f="8758" txt_i="3202" txt_f="3209">1 (0.2)</offsets></td><td><offsets xml_i="8767" xml_f="8774" txt_i="3210" txt_f="3217">3 (0.6)</offsets></td></tr><tr><td><offsets xml_i="8792" xml_f="8825" txt_i="3218" txt_f="3251"> Nervous system neoplasms, benign</offsets></td><td><offsets xml_i="8834" xml_f="8841" txt_i="3252" txt_f="3259">1 (0.2)</offsets></td><td><offsets xml_i="8850" xml_f="8857" txt_i="3260" txt_f="3267">2 (0.4)</offsets></td></tr><tr><td><offsets xml_i="8875" xml_f="8913" txt_i="3268" txt_f="3306"> Ocular neoplasms, benign or malignant</offsets></td><td><offsets xml_i="8922" xml_f="8929" txt_i="3307" txt_f="3314">3 (0.6)</offsets></td><td><offsets xml_i="8938" xml_f="8945" txt_i="3315" txt_f="3322">2 (0.4)</offsets></td></tr><tr><td><offsets xml_i="8963" xml_f="9006" txt_i="3323" txt_f="3366"> Plasma cell neoplasms, benign or malignant</offsets></td><td><offsets xml_i="9015" xml_f="9022" txt_i="3367" txt_f="3374">1 (0.2)</offsets></td><td><offsets xml_i="9031" xml_f="9032" txt_i="3375" txt_f="3376">0</offsets></td></tr><tr><td><offsets xml_i="9050" xml_f="9095" txt_i="3377" txt_f="3422"> Renal and urinary tract neoplasms, malignant</offsets></td><td><offsets xml_i="9104" xml_f="9111" txt_i="3423" txt_f="3430">2 (0.4)</offsets></td><td><offsets xml_i="9120" xml_f="9127" txt_i="3431" txt_f="3438">1 (0.2)</offsets></td></tr><tr><td><offsets xml_i="9145" xml_f="9183" txt_i="3439" txt_f="3477"> Reproductive neoplasms female, benign</offsets></td><td><offsets xml_i="9192" xml_f="9199" txt_i="3478" txt_f="3485">2 (0.4)</offsets></td><td><offsets xml_i="9208" xml_f="9215" txt_i="3486" txt_f="3493">1 (0.2)</offsets></td></tr><tr><td><offsets xml_i="9233" xml_f="9274" txt_i="3494" txt_f="3535"> Reproductive neoplasms female, malignant</offsets></td><td><offsets xml_i="9283" xml_f="9290" txt_i="3536" txt_f="3543">2 (0.4)</offsets></td><td><offsets xml_i="9299" xml_f="9306" txt_i="3544" txt_f="3551">4 (0.8)</offsets></td></tr><tr><td><offsets xml_i="9324" xml_f="9363" txt_i="3552" txt_f="3591"> Reproductive neoplasms male, malignant</offsets></td><td><offsets xml_i="9372" xml_f="9379" txt_i="3592" txt_f="3599">2 (0.4)</offsets></td><td><offsets xml_i="9388" xml_f="9395" txt_i="3600" txt_f="3607">3 (0.6)</offsets></td></tr><tr><td><offsets xml_i="9413" xml_f="9462" txt_i="3608" txt_f="3657"> Respiratory and mediastinal neoplasms, malignant</offsets></td><td><offsets xml_i="9471" xml_f="9478" txt_i="3658" txt_f="3665">6 (1.2)</offsets></td><td><offsets xml_i="9487" xml_f="9494" txt_i="3666" txt_f="3673">2 (0.4)</offsets></td></tr><tr><td><offsets xml_i="9512" xml_f="9538" txt_i="3674" txt_f="3700"> Skin neoplasms, malignant</offsets></td><td><offsets xml_i="9547" xml_f="9555" txt_i="3701" txt_f="3709">11 (2.1)</offsets></td><td><offsets xml_i="9564" xml_f="9571" txt_i="3710" txt_f="3717">9 (1.8)</offsets></td></tr><tr><td><offsets xml_i="9589" xml_f="9619" txt_i="3718" txt_f="3748"> Soft tissue neoplasms, benign</offsets></td><td><offsets xml_i="9628" xml_f="9635" txt_i="3749" txt_f="3756">3 (0.6)</offsets></td><td><offsets xml_i="9644" xml_f="9651" txt_i="3757" txt_f="3764">4 (0.8)</offsets></td></tr><tr><td><offsets xml_i="9669" xml_f="9711" txt_i="3765" txt_f="3807"> Soft tissue sarcomas, benign or malignant</offsets></td><td><offsets xml_i="9720" xml_f="9721" txt_i="3808" txt_f="3809">0</offsets></td><td><offsets xml_i="9730" xml_f="9737" txt_i="3810" txt_f="3817">1 (0.2)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="9783" xml_f="9792" txt_i="3818" txt_f="3827">Data are </offsets><italic><offsets xml_i="9800" xml_f="9801" txt_i="3827" txt_f="3828">n</offsets></italic><offsets xml_i="9810" xml_f="9837" txt_i="3828" txt_f="3855"> (%), in alphabetical order</offsets></p><p><offsets xml_i="9844" xml_f="10031" txt_i="3856" txt_f="4043">All patients with neoplasm-coded adverse events (whether considered serious or non-serious) as reported by the investigator are included. Patients may have had more than one adverse event</offsets></p><p><sup><offsets xml_i="10043" xml_f="10044" txt_i="4044" txt_f="4045">a</offsets></sup><offsets xml_i="10050" xml_f="10175" txt_i="4045" txt_f="4170">Includes MedDRA System Organ Class ‘Neoplasm benign, malignant and unspecified (including cysts and polyps)’ (version 10.0) [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="10207" xml_f="10208" txt_i="4170" txt_f="4171">6</offsets></xref><offsets xml_i="10215" xml_f="10216" txt_i="4171" txt_f="4172">]</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="10258" xml_f="10946" txt_i="4174" txt_f="4862">The overall number of patients with neoplasms (using the standard MedDRA coding dictionary) occurring during the trial was similar in the two treatment groups: 57 patients (11.1%) in the insulin glargine group vs 62 patients (12.3%) in the NPH insulin group, with an RR for insulin glargine of 0.90 (95% CI 0.64–1.26). In addition, when only the number of patients with malignant neoplasms reported as serious treatment-emergent events was captured, the rate was also similar in both treatment groups: 20 patients (3.9%) with 23 events in the insulin glargine group vs 31 patients (6.2%) with 32 events in the NPH insulin group, with an RR for insulin glargine of 0.63 (95% CI 0.36–1.09).</offsets></p><p><offsets xml_i="10953" xml_f="11217" txt_i="4863" txt_f="5127">The number of patients with malignant breast tumours reported was also similar between the two treatment groups: three patients in the insulin glargine group (all reported as serious) compared with five patients (four reported as serious) in the NPH insulin group.</offsets></p><p><offsets xml_i="11224" xml_f="11692" txt_i="5128" txt_f="5596">The RR estimate of all malignant breast tumour cases, including non-serious cases (three in the insulin glargine group vs five in the NPH insulin group) numerically favours insulin glargine (RR 0.59, 95% CI 0.14–2.44). Although the 95% CI includes 2, it must be noted that due to the small numbers of patients and the small number of cases, there was only a 22% power to reject a doubling in the risk (RR 2.0) of developing this tumour, should the true risks be equal.</offsets></p><p><offsets xml_i="11699" xml_f="11927" txt_i="5597" txt_f="5825">Considering all neoplasms (RR 0.9) and all malignant neoplasms (RR 0.63), the results numerically favour insulin glargine with 95% upper CI limits of 1.26 and 1.09, respectively, indicating at most a 26% and 9% increase in risk.</offsets></p><p><offsets xml_i="11934" xml_f="12374" txt_i="5826" txt_f="6266">In summary, this study is the longest controlled treatment comparison of insulin glargine versus NPH insulin in patients with type 2 diabetes mellitus. No new safety issues emerged for either insulin studied based on the data from this 5 year trial. Additional data reported here also confirm that there was no evidence of any difference in the rate of benign or malignant tumour development with insulin glargine compared with NPH insulin.</offsets></p></body><back><ack><title>Duality of interest</title><p>J. Rosenstock has received grants for research from and/or has been a consultant to Amylin, Boehringer-Ingelheim, Bristol-Myers Squibb, Centocor, Eli Lilly, Emisphere, GlaxoSmithKline, Johnson &amp; Johnson, MannKind, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sankyo, sanofi-aventis and Takeda. V. Fonseca has received research support (to Tulane University) with grants from GlaxoSmithKline, Novartis, Novo Nordisk, Takeda, Astra-Zeneca, Pfizer, sanofi-aventis, Eli Lilly, Daiichi-Sankyo, Novartis, the National Institutes of Health (NIH) and the American Diabetes Association (ADA), and honoraria for consulting and lectures from GlaxoSmithKline, Novartis, Takeda, Pfizer, sanofi-aventis and Eli Lilly. J. McGill has received grant support (to Washington University) from sanofi-aventis, Pfizer, Eli Lilly, Novo Nordisk, Novartis, GlaxoSmithKline, Elixir, Tolerx, Biodel, MannKind, Takeda; served on advisory boards and speakers' bureaus for sanofi-aventis and Novo Nordisk, and on speakers' bureaus for Eli Lilly, Merck, Novartis, Daiichi-Sankyo, Forest and GlaxoSmithKline; and has been a consultant/advisor for Merck, Novo Nordisk, Elixir, MannKind and Amgen. I. Hramiak has received research grant support from Pfizer, sanofi-aventis, Novo Nordisk and Eli Lilly, and has served on advisory boards for GlaxoSmithKline, Novo Nordisk, sanofi-aventis and Merck. J.-P. Hallé has received grants for research from and/or has been a consultant and/or on the speaker bureau of Bristol-Myers Squibb, ConjuChem, Bellus Health, Eli Lilly, GlaxoSmithKline, Merck Frosst, Novartis, Novo Nordisk, Pfizer, Roche, sanofi-aventis and Takeda. M. Riddle has received grants for research and/or honoraria for consulting or lectures from Amylin, Lilly, the Amylin-Lilly Alliance, Novo Nordisk, Pfizer, sanofi-aventis and Valeritas. P. Johnston is an employee of, and holds stock options from sanofi-aventis. M. Davis has received research support from sanofi-aventis.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>McGill</surname><given-names>JB</given-names></name><etal></etal></person-group><article-title>Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study</article-title><source>Diabetologia</source><year>2009</year></citation><citation citation-type="display-unstructured">Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. doi:10.1007/s00125-009-1415-7 </citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Currie</surname><given-names>CJ</given-names></name><name><surname>Poole</surname><given-names>CD</given-names></name><name><surname>Gale</surname><given-names>EAM</given-names></name></person-group><article-title>The influence of glucose-lowering therapies on cancer risk in type 2 diabetes</article-title><source>Diabetologia</source><year>2009</year></citation><citation citation-type="display-unstructured">Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. doi:10.1007/s00125-009-1440-6 <pub-id pub-id-type="pmid">19572116</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hemkens</surname><given-names>LG</given-names></name><name><surname>Grouven</surname><given-names>U</given-names></name><name><surname>Bender</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study</article-title><source>Diabetologia</source><year>2009</year></citation><citation citation-type="display-unstructured">Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. doi:10.1007/s00125-009-1418-4 <pub-id pub-id-type="pmid">19565214</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colhoun</surname><given-names>HM</given-names></name><collab>SDRN Epidemiology Group</collab></person-group><article-title>Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group</article-title><source>Diabetologia</source><year>2009</year></citation><citation citation-type="display-unstructured">Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. doi:10.1007/s00125-009-1453-1 </citation></ref><ref id="CR5"><label>5.</label><citation citation-type="other">Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. doi:10.1007/s00125-009-1444-2</citation></ref><ref id="CR6"><label>6.</label><citation citation-type="other">MedDRA—the Medical Dictionary for Regulatory Activities (2009) Available from <ext-link ext-link-type="uri" xlink:href="http://www.meddramsso.com/MSSOWeb/index.htm">www.meddramsso.com/MSSOWeb/index.htm</ext-link>, accessed 25 June 2009</citation></ref><ref id="CR7"><label>7.</label><citation citation-type="other">ClinicalStudyResults.org (2009) Available from <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudyresults.org/">www.clinicalstudyresults.org/</ext-link>, accessed 25 June 2009</citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>MedDRA</term><def><p>Medical Dictionary for Regulatory Activities</p></def></def-item><def-item><term>NPH</term><def><p>Neutral protamine Hagedorn</p></def></def-item></def-list></glossary></back></article>